Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Reworked Deal With Ipsen Gives GTx Extended Runway To Get Toremifene To Finish Line

This article was originally published in The Pink Sheet Daily

Executive Summary

GTx needs to run a second Phase III trial of the prostate cancer drug due to a "complete response" letter from FDA.

You may also be interested in...

FDA's "Complete Response" On GTx's Toremifene Moves The Goal Posts, CEO Says

Having gone through the special protocol assessment process, the sponsor was surprised by the request for a second pivotal trial and another clinical trial on effects on cancer.

GTx Files Toremifene For Prostate Cancer-Related Bone Loss

Biopharma is seeking a priority review for 80 mg toremifene, already marketed as Fareston at a 60 mg dose for breast cancer.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts